

- C1*
- Conclude*
- C102*
41. (Amended) The method according to claim 40 wherein at least one HIV reverse transcriptase inhibitor is AZT/ zidovudine, 3TC, lamivudine, ddI/didanosine, ddC/zalcitabine, d4T/stavudine, abacavir, 159U89, hydroxyurea/HO, nucleoside RT potentiator, nevirapine, delavirdine, efavirenz, adefovir dipivoxil, or bis-POM PMEA.
42. (Amended) The method according to claim 40 wherein at least one HIV protease inhibitor is saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, VX-478, KNI-272, CGP-61755, or U-103017.

Please enter the following new claim:

- C2*
- C103*
46. (New) A method of inhibiting human immunodeficiency virus (HIV) replication comprising administering to a patient in need thereof, a combination of at least one compound exhibiting α_1 -antitrypsin (AAT) or AAT-like activity and one or more compounds selected from a group consisting of HIV reverse transcriptase inhibitors and HIV protease inhibitors, for a time and under conditions effective to inhibit HIV replication.

REMARKS

Claims 1-45 were originally pending in the subject application. In response to a restriction requirement, claims 1-39 and 43-45 were withdrawn from consideration, without prejudice or disclaimer. Claims 40-42 are amended in the instant response to more particularly point out and distinctly claim the subject matter, which Applicants regard as their invention. New claim 46 is added herein. Therefore, the claims now under consideration are 40-42 and 46, as set forth herein. These new and amended claims are supported by the specification as filed, and Applicant believes that no new matter has been added. Applicants respectfully request that the Examiner reconsider and withdraw the various grounds of rejection of the claims.